Evaluation of a Gemcitabine-Doxorubicin-Paclitaxel Combination Schedule through Flow Cytometry Assessment of Apoptosis Extent Induced in Human Breast Cancer Cell Lines

Maria J. Serrano,1 Pedro Sánchez-Rovira,2 Ignacio Algarra,1 Ana Jaén,2 Ana Lozano2 and José J. Gaforio1,3

1Department of Health Sciences, Faculty of Experimental Sciences, University of Jaén, Paraje Las Lagunillas s/n, 23071-Jaén and 2Medical Oncology Department, Hospital Ciudad de Jaén, Avda. Ejercito Español s/n, 23007-Jaén, Spain

Combination chemotherapy with gemcitabine (Gem), doxorubicin (Dox), and paclitaxel (Pac) (GAT) has been considered attractive as first-line treatment in metastatic breast cancer. We compared the potential of various schedules of GAT to induce apoptosis on MDA-MB-231, MCF7, and T47D human breast cancer cell lines. The extent of apoptotic induction was analyzed by flow cytometry with 7-aminoactinomycin D (7AAD) staining. Differences between various schedules in terms of apoptotic induction were statistically significant (P<<<<0.05). The most effective apoptotic induction regimen was achieved by the sequence: Dox for 16 h followed by Pac+Gem. Schedules employing a 16-h interval between drug administrations induced higher levels of apoptosis in human breast cancer cell lines compared with schedules using a 4-h interval. The therapeutic efficacy of the experimental results shown in this paper has been clinically corroborated in a phase II trial in metastatic breast cancer patients.

Key words: Breast cancer — Gemcitabine — Doxorubicin — Paclitaxel — Apoptosis

Clinical trials designed to evaluate the effectiveness and safety of new treatments for patients with all stages of breast cancer are under way. Combination therapy offers exciting possibilities of enhanced antitumor efficacy. In fact, the most effective proven chemotherapeutic regimens are combinations of active antineoplastic agents. Criteria for an effective combination include use of drugs with different mechanisms of action, relative non-cross-resistance, and partially non-overlapping toxicities. Tumor heterogeneity and the presence of subsets of cells resistant to certain drugs provide a rationale for treatment with multiple non-cross-resistant drugs. Several groups have reported that the combination of doxorubicin (Dox) plus paclitaxel (Pac) produces a high response rate, including complete responses, in metastatic breast cancer, but that this effect is offset by an 18% to 20% incidence of congestive heart failure.1 Furthermore, the schedule of Pac before Dox appears more toxic than that of Dox before Pac, in that Pac has been shown to increase the myocardial concentration of Dox if there is a relatively short interval between administration of the drugs.2 Gemcitabine (Gem) has also shown a wide range of antitumor activity and moderate toxicity in metastatic breast cancer, without cross-resistance with Pac and Dox.3,4 Thus, the combination of Gem-Dox-Pac is considered an attractive first-line treatment for these patients.

It is now well documented that cytotoxic chemotherapy induces an increase in apoptosis within 24 h after the start of treatment.5 Malignant transformation of breast epithelial cells is associated with a dysregulation of proliferation/apoptosis control mechanisms. It seems that alterations in the genes involved in the apoptosis pathway play a crucial role in the process of progression and invasion in breast carcinogenesis.6 Therefore, the study of apoptotic induction in breast tumor cells, an important underlying mechanism of the antitumor activity of chemotherapeutic combinations, is a subject of growing research. In this work, we investigated experimentally the effect of the chemotherapeutic combination of Gem-Dox-Pac on apoptotic induction in human breast cancer cells.

The main objective of this study was to evaluate the ability of this chemotherapeutic combination (Dox+Pac+Gem) to promote apoptosis in 3 human breast cancer cell lines: 2 estrogen and progesterone receptor positive (MCF-7, T47D), and 1 estrogen and progesterone receptor negative (MDA-MB-231). Because the interaction of Dox, Pac, and Gem is highly schedule- and time-dependent, we attempted to find the combination schedule with the highest antitumor activity and the lowest cardiotoxicity by adjusting the interval between Dox and Pac administration.

These results could be of great interest to the design of optimal clinical treatment scheduling in breast cancer patients, which could improve the therapeutic efficacy of the combination. Thus, this in vitro study on human cell
lines represents a rational step in the formulation of the most effective treatment schedule.

MATERIALS AND METHODS

Cell lines  Breast carcinoma MDA-MB-231 (estrogen and progesterone receptor-negative), T47D, and MCF-7 cells (both estrogen and progesterone receptor-positive) were obtained from the American Type Culture Collection. All cells were grown as monolayers in Roswell Park Memorial Institute (RPMI) 1640 medium, supplemented with 2 mM L-glutamine, 10% heat-inactivated fetal bovine serum, and a 1% penicillin-streptomycin mixture, at 37°C in a 5% carbon dioxide atmosphere. Cells were grown to confluence and passaged with the use of trypsin ethylenediaminetetraacetic acid (EDTA). Cells in the exponential growth phase were used for all experiments.

Drugs  Paclitaxel ("Taxol"), supplied in a "Cremophor" EL (polyoxyethylated castor oil, BASF Aktiengesellschaft, Ludwigshafen, Germany, and ethanol solution), was purchased from Bristol-Myers Squibb Oncology, Princeton, New Jersey. Doxorubicin ("Farmiblastina") was purchased from Pharmacia & Upjohn, Peapack, New Jersey. Gemcitabine ("Gemzar", Eli Lilly and Company, Indianapolis, Indiana) was supplied as a lyophilized powder and diluted with sterile sodium chloride 0.9% at a concentration of 20 mg/ml, divided into aliquots, and stored at −70°C until used. Drug stocks were freshly diluted in culture medium before each experiment.

Chemosensitivity assays  Cell survival in untreated or treated cells was assessed by a 7-day MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) (Sigma Chemical Company, St. Louis, Missouri) assay. MTT was dissolved in phosphate-buffered saline (PBS) at 5 mg/ml and the solution was filtered. Cells were collected during the exponential growth phase of culture by trypsinization and seeded at 2×10³ cells per well in 96-well plates (100 µl of cell suspension per well). At 24 h after plating, 100 µl of fresh culture medium, with or without drugs, was added to the wells. Cells were exposed to the drugs for 72 h. At the end of drug exposure, the medium was removed from the plates and 200 µl of fresh culture medium, with or without drugs, was added to the wells. Cells were exposed to the drugs for 72 h. This assay is a measure of longer-term cytotoxicity rather than apoptotic endpoints. At the end of drug exposure, the medium was removed from the plates and 200 µl of fresh culture medium, with or without drugs, was added to the cells and incubated for an additional 96 h. After incubation, 40 µl of stock MTT solution was added and the plates were incubated at 37°C in 5% carbon dioxide for 4 h. In cell culture, MTT is converted from a yellow-colored salt to a purple-colored formazan by cleavage of the tetrazolium ring by mitochondrial dehydrogenases, the activity of which is linearly related to the cell number. Acid-isopropanol (100 µl of 0.04 N HCl in isopropanol) was added to all wells and mixed thoroughly to dissolve the formazan crystals. Absorbance at 550 nm (reference wavelength of 620 nm) was determined in an enzyme-linked immunosorbent assay (ELISA) reader (Whittaker Microplate Reader 2001; Anthos Labtec Instruments, Salzburg, Austria). Survival was expressed as the percentage of viable cells in treated samples relative to nontreated control cells.

Analysis of apoptosis by flow cytometry with 7-aminoactinomycin D (7AAD) staining  This assay was developed according to the method previously described by Schmid et al. and validated by Philpott et al. Briefly, 7AAD (Sigma Chemical Company) was dissolved in acetone and diluted in PBS to a concentration of 200 µg/ml. This solution was kept at −20°C and protected from light until use. A total of 100 µl of 7AAD solution was added to 10⁶ cells suspended in 1 ml of PBS and mixed well. Cells were incubated in the dark for 20 min at 4°C and harvested by low-speed centrifugation. Finally, cells were resuspended in 500 µl of 2% paraformaldehyde solution and analyzed by flow cytometry using an EPICS Elite ESP flow cytometer (Coulter, Hialeah, Florida) within 30 min of fixation. Scattergrams were generated by combining

![Fig. 1. Cell viability assessed by MTT assay. Dose-response curves of MDA-MB-231 cell lines exposed to single drugs (paclitaxel, doxorubicin, and gemcitabine) for 72 h. Results are mean values±standard deviation of three independent experiments in triplicate. Scalar drug concentrations (X-axis) are expressed in µg/ml.](image-url)
forward light scatter with 7AAD fluorescence (FL3) and regions were drawn around clear-cut populations having negative (live cells), dim (early-apoptotic cells), and bright fluorescence (late-apoptotic/dead cells).

Following cell treatment, all cells were stained with 7AAD, which together with flow cytometry, allowed the easy quantitation of live, apoptotic, and late-apoptotic/dead cells. The whole nucleated cell population was analyzed. Unstained tumor cell lines were used as negative controls.

The 7AAD method and flow cytometry were used to assess the induction of apoptosis of breast cancer cells by each drug for an exposure period of 24 h. We also used this method to determine whether the induction of apoptosis by this drug combination could be improved by varying the sequence and schedules of Dox, Pac, and Gem. We used 4 schedules of drug administration: 1) cell exposure to Dox for 4 h, followed by Pac for 24 h, a 24-h washout period, and 24-h treatment with Gem; 2) exposure to Dox for 4 h, followed by Pac for 24 h, a 48-h washout period, and 24-h treatment with Gem; 3) exposure to Dox for 16 h, followed by Pac+Gem for 48 h, and a 48-h washout period; and 4) exposure to Dox for 16 h, followed by Pac+Gem for 96 h. Differences between treated cell lines were statistically analyzed by using the two-tailed Student’s t test. A P value <0.05 was considered statistically significant.

RESULTS

Effect of individual drugs on cell growth The colorimetric MTT assay was used to determine the effect of individual drugs on cell survival of the three cell lines evaluated (MDA-MB-231, MCF7, and T47D) as shown in Figs. 1, 2 and 3. The scalar drug concentrations used were 0.01, 0.1, and 1 µg/ml for Pac, 0.025, 0.05, and 0.5 µg/ml for Dox; and 0.1, 1, and 10 µg/ml for Gem. The drug concentrations selected were close to the IC50 detected for each of the three cell lines employed in these experiments. This assay was previously performed in our laboratory to establish the optimal drug concentrations to be further used in the analysis of apoptotic induction (Figs. 1, 2 and
3). The extent of growth inhibition rates (% survival) for each drug was as follows: T47D > MCF7 > MDA-MB-231 for Pac; T47D > MDA-MB-231 > MCF7 for Dox; and a similar effect across the 3 cell lines for Gem.

**Analysis of apoptosis induced by individual drugs** The objectives were i) to analyze if Pac, Dox and Gem induce apoptosis in the three breast cancer cell lines tested, and ii) to determine if the apoptosis induced by these chemotherapeutic drugs is accurately assessed by the 7AAD method. Flow cytometric analysis using 7AAD was then used to assess the induction of apoptosis in breast cancer cells to a 24-h exposure of the individual drugs. The scalar drug concentrations used for MDA-MB-231, MCF7, and T47D cell lines and the corresponding drug-induced apoptotic effect of each drug are presented in Tables I, II and III, respectively. A wide range of concentrations of each of the chemotherapeutic drugs was used. Our results show that significant alteration of the apoptotic cell population was detected by this assay, and the percentage of early-apoptotic and late-apoptotic/dead cells increased in a dose-dependent manner for all drugs. We found that at low drug concentrations an increase of early apoptotic cells was observed while at high concentrations an increase of late-apoptotic and late-apoptotic/dead cells was observed. It is important to note that differences in the sensitivity to chemotherapeutic drugs among the three breast cancer cell lines were observed. Thus, MDA-MB-231 cells were found to be highly sensitive to the apoptotic drugs compared to MCF-7 and T47D cells. The extent of apoptosis induced in tumor cell lines for all drugs tested was as follows: MDA-MB-231 > MCF7 > T47D.

**Analysis of apoptosis induced by varying drug sequence and schedule** Flow cytometric analysis using 7AAD was also used to assess the drug-induced apoptotic effect of different drug sequences and schedules on the three cell lines (MDA-MB-231, MCF-7 and T47D) (Tables IV, V and VI, respectively). The sequence/schedules that we compared in this study are: 1) Dox for 4 h, followed by Pac for 24 h, a 24 h washout period, and Gem for 24 h; 2) Dox for 4 h, followed by Pac for 24 h, a 48 h washout period, and Gem for 24 h; 3) Dox for 16 h, followed by (Pac+Gem) for 48 h, and a 48 h washout period; 4) Dox for 16 h, followed by (Pac+Gem) for 96 h. The scalar drug concentrations used for this evaluation were: 0.01 µg/ml for Pac, 0.025 µg/ml for Dox, and 0.1 µg/ml for Gem. These doses were selected on the basis of results shown in Figs. 1–3 and Tables I–III. At these doses, we found that the drugs are cytotoxic by inducing

### Table I. Drug-induced Apoptosis in MDA-MB-231 Cell Lines Retreated for 24 Hours

| Treatment | % Live cells | % Early-apoptotic cells | % Late-apoptotic and dead cells |
|-----------|--------------|------------------------|-----------------------------|
| Untreated control | 89.4±4.4 | 6.7±2.9 | 3.9±1.5 |
| Paclitaxel (µg/ml) | | | |
| 0.001 | 73 | 23.9 | 3.1 |
| 0.005 | 36.9 | 50.2 | 12.9 |
| 0.01 | 31.6 | 54 | 14.4 |
| Doxorubicin (µg/ml) | | | |
| 0.01 | 67.2 | 30 | 2.8 |
| 0.025 | 60 | 36.5 | 3.5 |
| 0.05 | 32.2 | 63.1 | 4.7 |
| Gemcitabine (µg/ml) | | | |
| 0.01 | 70.5 | 27 | 2.5 |
| 0.05 | 61 | 34.6 | 4.4 |
| 0.1 | 57.1 | 38.7 | 4.2 |

*a* Cells were incubated with different concentrations of doxorubicin, paclitaxel, or gemcitabine; apoptosis was determined after 24 h by flow cytometry using 7-aminoactinomycin D (7AAD) staining. Results are expressed as the mean percentage of live, early-apoptotic, or late-apoptotic/dead cells of at least 3 experiments.  

*b* Mean percentage±standard deviation of experimental data detected in control samples.
apoptosis (assessed chiefly as early-apoptotic cells). In addition, similar concentrations of Pac, Dox and Gem were also used by Zoli et al. in their drug combination studies. The results show a similar effect of the sequence/schedules 3 and 4 with regard to apoptosis induction on the three cancer cell lines tested. If we compare sequence/schedules 1 and 2, the maximum apoptotic induction on the three cancer cell lines tested is achieved by the sequence/schedules 2. This is in agreement with the results obtained by Zoli et al. as they observed that the maximum cytocidal effect was achieved by the sequence 2. When the sums of the early-apoptotic and late-apoptotic/dead cells among schedules were compared, the schedules using a 16-h interval between drug administrations (sequence/schedules 3 and 4) induced higher levels of apoptosis compared with those using a 4-h interval (sequence/schedules 1 and 2) (P<0.05). These results were again similar for the three cancer cell lines tested (MDA-MB-231, MCF-7 and T47D).


DISCUSSION

To date, the effectiveness of new combination chemotherapy protocols for breast cancer patients has been based on the results obtained from clinical trials. One of the most important endpoints of clinical trials is identification of the optimal schedule of sequential drug administration. Our current study suggests that in vitro assessment of the extent of apoptosis induced by the combination regimen could be a good tool for identifying the most effective treatment schedule.

Apoptosis and cell proliferation determine the growth dynamics of breast carcinomas, including their response to drugs. Ellis and coworkers\(^\text{10, 11}\) showed that increased apoptosis is a common factor in breast cancer’s response to chemotherapy and that this change in apoptosis may predict the clinical response. We focused our study on the interaction between Dox, Pac, and Gem in terms of their antitumor activity to treat breast cancer. We demonstrated that each drug inhibits the in vitro growth of MDA-MB-231, T47D, and MCF7 breast cancer cell lines (Figs. 1–3).

The capacity of Dox, Pac, and Gem to induce apoptosis in tumor cells is well established.\(^\text{12–15}\) There are many ways to detect apoptosis: detection of typical morphologic features of the cell population by light or electron microscopy, time-lapse photography, detection of DNA fragmentation by gel electrophoresis, the TUNEL assay, and flow cytometry-based methods (for example, PI staining). In this study, flow cytometric analysis with 7AAD was used\(^\text{7, 8}\) to determine the extent of drug-induced apoptosis on tumor cell lines. 7AAD stains live, apoptotic, and dead cells differentially because of the altered accessibility of DNA in each subpopulation. This method has several advantages over the methods outlined above: it gives information about cell numbers, it does not require dye permeation through the cell membrane, and moreover, large numbers of cells can be rapidly and accurately examined by flow cytometry. The main advantage is that it is able to identify early-apoptotic cells (cells retaining membrane integrity) separately from late-apoptotic/dead cells (membrane integrity has been lost). This is of particular interest in our study, where apoptosis is not induced simultaneously in all cells.

The utility of the 7AAD method is well established in the assessment of apoptosis in human tumors. Pallis and coworkers\(^\text{16}\) used flow cytometric analysis with 7AAD to analyze the chemosensitivity of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes. The 7AAD method was also performed to detect apoptosis induced in human malignant melanoma cell lines\(^\text{17}\) and in breast cancer cell line MDA-MB-231.\(^\text{18}\) The results we obtained using the 7AAD method suggest that it could be a good tool to detect and check the extent of apoptosis induced by chemotherapeutic drugs in human breast tumor cell lines. In all tumor cell lines, the extent of apoptosis induced by the individual drugs (Pac, Dox, or Gem) was MDA-MB-231 > MCF7 > T47D, and the increase in the percentage of early-apoptotic and late-apoptotic/dead cells was dose-dependent (Tables I, II and III). A wide range of drug concentrations was used to assess cell apoptosis and we found that, in general, at low drug concentrations an increase of early-apoptotic cells was detected while at high drug concentrations an increase of late-apoptotic/dead cells was observed. These results are in agreement with the statement that at high concentrations most chemotherapeutic drugs lead to the inhibition of tumor cell proliferation by the induction of necrosis.

We found only one study that presented in vitro results with the Dox-Pac-Gem combination.\(^\text{9}\) They evaluated the cytotoxic effects of a combination of Dox, Pac, and Gem in BRC-230 and MCF7 human breast cancer cells. The maximum cytocidal effect was achieved by the sequence of Dox for 4 h, followed by Pac for 24 h, a 48-h washout period, and Gem for 24 h.

In this study, we have also presented data on the extent of apoptotic induction in MDA-MB-231, MCF7, and T47D human breast cancer cell lines by our proposed sequential combination of Dox, Pac, and Gem (Dox for 16 h, followed by Pac+Gem) and those proposed by Zoli and coworkers\(^\text{9}\) (Dox for 4 h, followed by Pac for 24 h, a 24 h washout period, and Gem for 24 h; and Dox for 4 h, followed by Pac for 24 h, a 48 h washout period, and Gem for 24 h) (Tables IV–VI). Cells were stained with 7AAD and then analyzed by flow cytometry. The best schedule of drug administration for the promotion of apoptosis was achieved by the sequence/schedule: exposure to Dox for 16 h, followed by Pac+Gem. This drug combination scheme was shown to be active in both estrogen receptor-negative and -positive breast cancer cell lines, although there were significantly more apoptotic cells observed in estrogen- and progesterone-negative cells (MDA-MB-231) than in estrogen- and progesterone-positive cells (MCF7 and T47D). These data are in agreement with the results obtained when we used the individual chemotherapeutic drugs (Tables I–III).

In experimental estrogen deprivation conditions, as in this study, the apoptotic effects of the individual drugs and the chemotherapeutic combination schedules tested were higher in estrogen receptor-negative breast cancer cell lines (MDA-MB-231) than in estrogen receptor-positive cell lines (MCF7 and T47D). Zoli et al.\(^\text{9}\) also reported a higher cytocidal effect in estrogen receptor-negative breast cancer cell lines than in estrogen receptor-positive cell lines. It is important to note that estrogen-negative breast cancers are highly aggressive and they must be treated with polychemotherapy. In this context, Rochefort et al.\(^\text{19}\) found that estrogens in estrogen-positive breast cancers have a dual effect, since they stimulate tumor growth, but
inhibit invasion and motility. On the other hand, no direct involvement of estrogen and/or progesterone receptors in apoptotic cell death susceptibility induced by chemotherapeutic drugs has been described so far.

Theoretically, Dox separated from Pac by a 16-h washout interval could minimize the inhibitory effects exerted by Pac on P-glycoprotein-mediated biliary clearance of Dox, which could reduce the risk of severe cardiotoxicity. The following phase II trial conducted by our group,20,21) supports our belief that the 16-h interval between Dox and Pac could reduce the risk of cardiotoxicity. The toxicity and activity of Dox at 30 mg/m² (day 1), Pac at 135 mg/m² (day 2), and Gem at 2500 mg/m² (day 2) given biweekly in a 28-day cycle for 6 cycles was evaluated as first-line treatment in 41 patients with metastatic breast cancer. Dox was administered 16 h before Pac. The activity observed was extremely encouraging, with an overall response rate of 82.9% and a complete response rate of 43.9%. Median duration of response was 14.1 months and a complete response rate of 82.9% and a complete response rate of 43.9%. Median duration of response was 14.1 months and a complete response rate of 82.9% and a complete response rate of 43.9%. Median duration of response was 14.1 months and a complete response rate of 82.9% and a complete response rate of 43.9%.

We propose that the 16-h interval between Dox and Pac, which could reduce the risk of cardiotoxicity. The following phase II trial conducted by our group,20,21) supports our belief that the 16-h interval between Dox and Pac could reduce the risk of cardiotoxicity. The toxicity and activity of Dox at 30 mg/m² (day 1), Pac at 135 mg/m² (day 2), and Gem at 2500 mg/m² (day 2) given biweekly in a 28-day cycle for 6 cycles was evaluated as first-line treatment in 41 patients with metastatic breast cancer. Dox was administered 16 h before Pac. The activity observed was extremely encouraging, with an overall response rate of 82.9% and a complete response rate of 43.9%. Median duration of response was 14.1 months and a complete response rate of 82.9% and a complete response rate of 43.9%. Median duration of response was 14.1 months and a complete response rate of 82.9% and a complete response rate of 43.9%.

**ACKNOWLEDGMENTS**

Supported in part by research grants from the Asociación Jienense de Estudios Oncológicos "LOFERSAN" and COFIMAN SL.

*(Received October 30, 2001/Revised March 8, 2002/Accepted March 13, 2002)*

**REFERENCES**

1) Sparano, J. A., Hu, P., Rao, R. M., Falkson, C. I., Wolff, A. C. and Wood, W. C. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group study. *J. Clin. Oncol.*, 17, 3828–3834 (1999).

2) Gianni, L., Vigano, L., Locatelli, A., Capri, G., Giani, A., Tenerz, E. and Bonadonna, G. Human pharmacokinetic characterization and *in vitro* study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. *J. Clin. Oncol.*, 15, 1906–1915 (1997).

3) Spielmann, M., Llombart-Cussac, A., Kalla, S., Espie, M., Namer, M., Ferrero, J. M., Dieras, V., Fumoleau, P., Cuvier, C., Perrocheau, G., Ponzo, A., Kayitialire, L. and Pouillart, P. Single-agent gemcitabine is active in previously treated metastatic breast cancer. *Oncology*, 60, 303–307 (2001).

4) Sanchez-Rovira, P., Mohedano, N., Moreno, M. A., Gonzalez, E., Juen, A., Medina, B., Fernandez, M. and Lozano, A. Preliminary results from an early phase II combination of gemcitabine and Taxol in metastatic breast cancer. *Eur. J. Cancer*, 33 (Suppl. 8), S154 (1997).

5) Lowe, S. W. and Lin, A. W. Apoptosis in cancer. *Carcinogenesis*, 21, 485–495 (2000).

6) Mommer, E., van Diest, P. J., Leonhart, A., Meijer, C. and Baak, J. P. Balance of cell proliferation and apoptosis in breast carcinogenesis. *Breast Cancer Res. Treat.*, 58, 163–169 (1999).

7) Schmid, I., Uittenbogaart, C. H., Keld, B. and Giorgi, J. V. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. *J. Immunol. Methods*, 170, 145–157 (1994).

8) Philpott, N. J., Turner, A. J., Scopes, J., Wetyl, M., Marsh, J. C., Gordon-Smith, E. C., Dalgleish, A. G. and Gibson, F. M. The use of 7-aminoactinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. *Blood*, 87, 2244–2251 (1996).

9) Zoli, W., Ricotti, L., Barzanti, F., Dal Susino, M., Frassinetti, G. L., Milandri, C., Casadei, D. and Amadori, D. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. *Int. J. Cancer*, 80, 413–416 (1999).

10) Ellis, P. A., Smith, I. E., McCarthy, K., Detre, S., Salter, J. and Dowsett, M. L. Preoperative chemotherapy induces apoptosis in early breast cancer. *Lancet*, 349, 848 (1997).

11) Ellis, P. A., Smith, I. E., Detre, S., Burton, S. A., Salter, J., A’Hern, R., Wals, G., Johnston, S. R. and Dowsett, M. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. *Breast Cancer Res. Treat.*, 48, 107–116 (1998).

12) Gazitt, Y., Rothenberg, M. L., Hilsenbeck, S. G., Fey, V., Thomas, C. and Montogomery, W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. *Int. J. Oncol.*, 13, 839–848 (1998).

13) Gan, Y., Wientjes, M. G., Lu, J. and Au, J. L. Cytostatic
and apoptotic effects of paclitaxel in human breast tumors. Cancer Chemother. Pharmacol., 42, 177–182 (1998).

14) Wang, L. G., Liu, X. M., Kreis, W. and Budman, D. R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol., 44, 355–361 (1999).

15) Gooch, J. L., Van Den Berg, C. L. and Yee, D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res. Treat., 56, 1–10 (1999).

16) Pallis, M., Syan, J. and Russell, N. H. Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34. Cytometry, 37, 308–313 (1999).

17) Ariza, M. E., Broome-Powell, M., Lahti, J. M., Kidd, V. J. and Nelson, M. A. Fas-induced apoptosis in human malignant melanoma cell lines is associated with the activation of the p34(cdc2)-related PITSLRE protein kinase. J. Biol. Chem., 274, 28505–28513 (1999).

18) Li, Y., Upadhyay, S., Bhuiyan, M. and Sarkar, F. H. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene, 18, 3166–3172 (1999).

19) Rochefort, H., Platet, N., Hayashido, Y., Deroçq, D., Lucas, A., Cunat, S. and Garcia, M. Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J. Steroid Biochem. Mol. Biol., 65, 163–168 (1998).

20) Sanchez-Rovira, P., Jaen, A., Gonzalez-Flores, E., Porras, I., Dueñas, R., Medina, B., Fernandez, M., Mohedano, N. and Lozano, A. Biweekly gemcitabine-adriamycin-paclitaxel combination (GAT) in metastatic breast cancer patients (MBC): results from a phase II trial. Proc. Am. Soc. Clin. Oncol., 19, 109a (2000).

21) Sanchez-Rovira, P., Jaen, A., Gonzalez-Flores, E., Porra, I., Dueñas, R., Medina, B., Mohedano, N., Fernandez, M., Martos, M. and Lozano, A. Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial. Oncology (Huntingt), 15 (Suppl. 3), 44–47 (2001).

22) Frassineti, G. L., Zoli, W., Silvestro, L., Serra, P., Milandrini, C., Tienghi, A., Gianni, L., Gentile, A., Salzano, E. and Amadori, D. Paclitaxel plus doxorubicin in breast cancer: an Italian experience. Semin. Oncol., 243 (Suppl. 17), S19–S25 (1997).